PNC Financial Services Group Inc. Sells 1,090 Shares of LivaNova PLC $LIVN

PNC Financial Services Group Inc. reduced its stake in LivaNova PLC (NASDAQ:LIVN) by 43.1% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,441 shares of the company’s stock after selling 1,090 shares during the period. PNC Financial Services Group Inc.’s holdings in LivaNova were worth $65,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in LIVN. AQR Capital Management LLC lifted its stake in LivaNova by 111.7% in the first quarter. AQR Capital Management LLC now owns 1,571,295 shares of the company’s stock valued at $60,809,000 after buying an additional 829,115 shares during the period. Nuveen LLC bought a new stake in shares of LivaNova in the 1st quarter valued at about $30,954,000. Hotchkis & Wiley Capital Management LLC raised its position in shares of LivaNova by 100.7% in the 1st quarter. Hotchkis & Wiley Capital Management LLC now owns 1,003,000 shares of the company’s stock valued at $39,398,000 after acquiring an additional 503,350 shares during the period. LSV Asset Management boosted its stake in LivaNova by 278.3% during the 1st quarter. LSV Asset Management now owns 438,498 shares of the company’s stock worth $17,224,000 after acquiring an additional 322,598 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in LivaNova by 13.5% during the 1st quarter. Vanguard Group Inc. now owns 2,666,880 shares of the company’s stock worth $104,755,000 after acquiring an additional 316,993 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Trading Down 1.1%

Shares of LivaNova stock opened at $63.11 on Tuesday. The company has a market capitalization of $3.45 billion, a price-to-earnings ratio of -16.22 and a beta of 1.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 1.09. The business has a fifty day simple moving average of $54.31 and a two-hundred day simple moving average of $50.38. LivaNova PLC has a 1 year low of $32.48 and a 1 year high of $64.08.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. The Goldman Sachs Group set a $55.00 target price on shares of LivaNova and gave the company a “neutral” rating in a research note on Wednesday, October 1st. Weiss Ratings restated a “sell (d+)” rating on shares of LivaNova in a research report on Tuesday, November 25th. Barclays raised their price objective on LivaNova from $55.00 to $58.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 21st. Mizuho lifted their price target on shares of LivaNova from $65.00 to $70.00 and gave the company an “outperform” rating in a research note on Thursday, November 13th. Finally, Robert W. Baird boosted their price target on LivaNova from $63.00 to $70.00 and gave the company an “outperform” rating in a report on Thursday, November 13th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, LivaNova currently has an average rating of “Moderate Buy” and a consensus target price of $62.43.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.